These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2901345)

  • 1. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
    Bargmann CI; Weinberg RA
    EMBO J; 1988 Jul; 7(7):2043-52. PubMed ID: 2901345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
    Guy PM; Carraway KL; Cerione RA
    J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
    J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain.
    Wides RJ; Zak NB; Shilo BZ
    Eur J Biochem; 1990 May; 189(3):637-45. PubMed ID: 1972062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A subdomain in the transmembrane domain is necessary for p185neu* activation.
    Cao H; Bangalore L; Bormann BJ; Stern DF
    EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.
    Bargmann CI; Hung MC; Weinberg RA
    Cell; 1986 Jun; 45(5):649-57. PubMed ID: 2871941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
    Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
    Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
    Brandt-Rauf PW; Pincus MR; Chen JM
    J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain.
    Coulier F; Kumar R; Ernst M; Klein R; Martin-Zanca D; Barbacid M
    Mol Cell Biol; 1990 Aug; 10(8):4202-10. PubMed ID: 1695324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
    Sharpe S; Barber KR; Grant CW
    Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.
    Huang SS; Koh HA; Konish Y; Bullock LD; Huang JS
    J Biol Chem; 1990 Feb; 265(6):3340-6. PubMed ID: 1968062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF; Kamps MP; Cao H
    Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.
    Chen LI; Webster MK; Meyer AN; Donoghue DJ
    J Cell Biol; 1997 May; 137(3):619-31. PubMed ID: 9151669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and activation of the Syrian hamster neu proto-oncogene.
    Nakamura T; Ushijima T; Ishizaka Y; Nagao M; Arai M; Yamazaki Y; Ishikawa T
    Gene; 1994 Mar; 140(2):251-5. PubMed ID: 7908275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.
    Hung MC; Schechter AL; Chevray PY; Stern DF; Weinberg RA
    Proc Natl Acad Sci U S A; 1986 Jan; 83(2):261-4. PubMed ID: 3001730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
    EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
    Shu HK; Pelley RJ; Kung HJ
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neu and its ligands: from an oncogene to neural factors.
    Peles E; Yarden Y
    Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.